The aim of this study was to investigate the clinical relevance of BRAF V600E mutation status, cyclin D1 expression and MSI status of primary tumours of patients with mCRC treated with front-line 5FU-based chemotherapy. This evidence concerns the gene CCND1 and neoplasm.